2024版LI-RADS非放疗治疗反应算法在HCC局部联合免疫靶向治疗后的诊断效能
回顾性纳入132例(143个病灶)HCC患者,均接受局部治疗联合免疫靶向治疗后行肝切除术,以病理为参考标准比较LI-RADS非放疗TRA v2024与v2018的诊断效能。v2024的LR-TR Viable预测病理活性的敏感度66.3%、特异度95.2%,联合辅助特征后敏感度提升至87.1%且特异度无显著下降,整体优于v2018。
要点
- v2024 LR-TR Viable预测病理活性的敏感度66.3%、特异度95.2%。
- 联合辅助特征可将敏感度提升至87.1%,特异度90.5%无显著差异。
- v2024联合辅助特征整体诊断效能优于v2018。
核心结论
- LI-RADS非放疗TRA v2024联合辅助特征在评估HCC局部治疗联合免疫靶向治疗后肿瘤活性方面表现出优异诊断效能,并优于v2018。
研究设计与样本
- 由两名放射科医师独立根据LI-RADS非放疗TRA v2024和v2018在MRI上对病灶进行LR-TR分类,以肝切除术病理结果为参考标准。
- 采用McNemar检验比较两版本识别残留肿瘤活性的诊断效能。
诊断标准与关键数值
- v2024 LR-TR Viable类别预测病理活性的敏感度为66.3%(95%CI:57.1%-75.5%),特异度为95.2%(95%CI:84.2%-98.7%)。
- v2024 LR-TR Nonviable类别识别完全病理坏死的敏感度为76.2%(95%CI:63.3%-89.1%),特异度为95.1%(95%CI:90.8%-99.3%)。
- 联合辅助特征检测病理活性的敏感度为87.1%(对比66.3%,P<0.001),特异度为90.5%(对比95.2%,P=0.500)。
临床应用与阅片要点
- 在局部治疗联合免疫靶向治疗后的HCC疗效评估中,可采用LI-RADS非放疗TRA v2024进行LR-TR分类。
- 联合辅助特征可提高检测残留肿瘤活性的敏感度,减少漏诊,但需注意特异度可能轻度下降。
局限性
- 回顾性研究设计。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) nonradiation Treatment Response Assessment (TRA) version 2024 (v2024) in assessing treatment response of hepatocellular carcinoma (HCC) following downstaging locoregional therapy (LRT) plus immune-targeted therapy; to compare its diagnostic performance with LI-RADS TRA version 2018 (v2018); and to explore the added diagnostic value of its ancillary features (AFs).
METHODS: This retrospective study included patients with HCC who underwent LRT plus immune-targeted therapy followed by hepatectomy between January 2021 and December 2025. Two radiologists independently assigned LR-TR classifications to lesions on MRI according to the LI-RADS Nonradiation TRA v2024 and v2018. With pathological findings from hepatectomy as the reference standard, the sensitivity, specificity and accuracy of the two versions were calculated. Diagnostic performance for identifying residual tumor viability was compared using the McNemar test.
RESULTS: A total of 132 patients (19 women, 113 men; mean age, 55.9 ± 9.5 years [standard deviation]) with 143 treated HCC lesions were enrolled in this study. The LR-TR Viable category of v2024 yielded a sensitivity of 66.3% (95% confidence interval [CI]: 57.1%-75.5%) and a specificity of 95.2% (95% CI: 84.2%-98.7%) for predicting pathologic viability. For identifying complete pathologic necrosis, the LR-TR Nonviable category showed a sensitivity of 76.2% (95% CI: 63.3%-89.1%) and a specificity of 95.1% (95% CI: 90.8%-99.3%). The incorporation of AFs significantly improved the sensitivity for detecting pathologic viability (87.1% vs. 66.3%, P < 0.001), with no significant difference in specificity (90.5% vs. 95.2%, P = 0.500). Overall, LI-RADS nonradiation TRA v2024 integrated with AFs exhibited superior diagnostic performance relative to LI-RADS TRA v2018.
CONCLUSION: The LI-RADS nonradiation TRA v2024 incorporating AFs showed excellent diagnostic performance and outperformed LI-RADS TRA v2018 for assessing tumor viability in HCC patients treated with LRT plus immune-targeted therapy.
引用
- Yang H, Zhang Z, Han S, et al. Diagnostic performance of the 2024 LI-RADS nonradiation treatment response algorithm in hepatocellular carcinoma treated with locoregional plus immune-targeted therapy. Eur J Radiol. 2026. PMID: 42508275. doi:10.1016/j.ejrad.2026.113111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。